<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <committees>
      <billCommittees>
        <item>
          <name>Finance Committee</name>
          <chamber>Senate</chamber>
          <type>Standing</type>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2017-03-15T16:09:40Z</date>
            </item>
          </activities>
          <systemCode>ssfi00</systemCode>
          <subcommittees />
        </item>
      </billCommittees>
    </committees>
    <billType>S</billType>
    <laws />
    <version>1.0.0</version>
    <cosponsors>
      <item>
        <bioguideId>B000944</bioguideId>
        <middleName />
        <lastName>BROWN</lastName>
        <party>D</party>
        <identifiers>
          <lisID>136</lisID>
          <gpoId>8309</gpoId>
          <bioguideId>B000944</bioguideId>
        </identifiers>
        <sponsorshipDate>2017-03-15</sponsorshipDate>
        <firstName>SHERROD</firstName>
        <state>OH</state>
        <sponsorshipWithdrawnDate />
        <fullName>Sen. Brown, Sherrod [D-OH]</fullName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>H001069</bioguideId>
        <middleName />
        <lastName>Heitkamp</lastName>
        <party>D</party>
        <identifiers>
          <bioguideId>H001069</bioguideId>
          <lisID>2174</lisID>
          <gpoId />
        </identifiers>
        <sponsorshipDate>2017-03-15</sponsorshipDate>
        <firstName>Heidi</firstName>
        <state>ND</state>
        <sponsorshipWithdrawnDate />
        <fullName>Sen. Heitkamp, Heidi [D-ND]</fullName>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>T000464</bioguideId>
        <middleName />
        <lastName>Tester</lastName>
        <party>D</party>
        <identifiers>
          <bioguideId>T000464</bioguideId>
          <lisID>1829</lisID>
          <gpoId>8258</gpoId>
        </identifiers>
        <sponsorshipDate>2017-03-22</sponsorshipDate>
        <firstName>Jon</firstName>
        <state>MT</state>
        <sponsorshipWithdrawnDate />
        <fullName>Sen. Tester, Jon [D-MT]</fullName>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <createDate>2017-03-16T05:28:17Z</createDate>
    <originChamber>Senate</originChamber>
    <latestAction>
      <text>Read twice and referred to the Committee on Finance.</text>
      <actionDate>2017-03-15</actionDate>
      <links />
    </latestAction>
    <committeeReports />
    <recordedVotes />
    <introducedDate>2017-03-15</introducedDate>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <cboCostEstimates />
    <summaries>
      <billSummaries>
        <item>
          <text><![CDATA[<p><b>Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 </b></p> <p>This bill amends title XI (General Provisions) of the Social Security Act (SSAct) to&nbsp;require the public&nbsp;disclosure of certain information provided to the Department of Health and Human Services (HHS) by a pharmacy benefit manager (PBM)&nbsp;that contracts with: (1) a prescription drug&nbsp;plan (PDP) under Medicare or&nbsp;Medicare Advantage (MA),&nbsp;or (2) a qualified health benefits plan offered through an exchange established under the Patient Protection and Affordable Care Act.&nbsp;Specifically, HHS must publish on its website, with respect to each PBM, information&nbsp;regarding: (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies.</p> <p>As a condition of participation as a contractor&nbsp;under Medicare or MA, a PBM must pass&nbsp;on to&nbsp;a&nbsp;PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan.</p> <p>The bill also&nbsp;amends title XVIII (Medicare) of the SSAct to modify requirements&nbsp;regarding enrollees' access to negotiated drug prices.&nbsp;Current law requires&nbsp;a PDP sponsor&nbsp;to provide enrollees in Medicare&nbsp;or MA&nbsp;with access to negotiated&nbsp;drug prices that&nbsp;account for rebates and discounts. The bill requires&nbsp;that, with respect to a covered drug,&nbsp;a&nbsp;negotiated price (or,&nbsp;if necessary, an approximate negotiated price)&nbsp;be provided at the point of sale.</p>]]></text>
          <versionCode>00</versionCode>
          <actionDesc>Introduced in Senate</actionDesc>
          <name>Introduced in Senate</name>
          <updateDate>2017-03-15T04:00:00Z</updateDate>
          <actionDate>2017-03-15</actionDate>
          <lastSummaryUpdateDate>2017-07-24T22:01:20Z</lastSummaryUpdateDate>
        </item>
      </billSummaries>
    </summaries>
    <congress>115</congress>
    <relatedBills />
    <calendarNumbers />
    <title>Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017</title>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Government information and archives</name>
          </item>
          <item>
            <name>Health care costs and insurance</name>
          </item>
          <item>
            <name>Inflation and prices</name>
          </item>
          <item>
            <name>Medicare</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <sponsors>
      <item>
        <middleName />
        <byRequestType />
        <fullName>Sen. Wyden, Ron [D-OR]</fullName>
        <lastName>WYDEN</lastName>
        <party>D</party>
        <state>OR</state>
        <identifiers>
          <gpoId>8265</gpoId>
          <bioguideId>W000779</bioguideId>
          <lisID>1247</lisID>
        </identifiers>
        <bioguideId>W000779</bioguideId>
        <firstName>RON</firstName>
      </item>
    </sponsors>
    <actions>
      <actionTypeCounts>
        <referredToCommittee>1</referredToCommittee>
        <introducedInSenate>1</introducedInSenate>
      </actionTypeCounts>
      <item>
        <actionDate>2017-03-15</actionDate>
        <committee>
          <systemCode>ssfi00</systemCode>
          <name>Finance Committee</name>
        </committee>
        <links />
        <sourceSystem>
          <code>0</code>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Finance.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2017-03-15</actionDate>
        <actionCode>10000</actionCode>
        <committee />
        <type>IntroReferral</type>
        <text>Introduced in Senate</text>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <links />
      </item>
      <actionByCounts>
        <senate>2</senate>
      </actionByCounts>
    </actions>
    <amendments />
    <titles>
      <item>
        <title>Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017</title>
        <titleType>(Extracted from GPO) Short Titles as Introduced</titleType>
        <chamberCode />
        <chamberName />
        <parentTitleType />
      </item>
      <item>
        <title>Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017</title>
        <titleType>Short Titles as Introduced</titleType>
        <chamberCode />
        <chamberName />
        <parentTitleType />
      </item>
      <item>
        <title>A bill to amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.</title>
        <titleType>Official Title as Introduced</titleType>
        <chamberCode />
        <chamberName />
        <parentTitleType />
      </item>
      <item>
        <title>Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017</title>
        <titleType>Display Title</titleType>
        <chamberCode />
        <chamberName />
        <parentTitleType />
      </item>
    </titles>
    <billNumber>637</billNumber>
    <updateDate>2017-07-27T04:49:31Z</updateDate>
    <notes />
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

